Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sarepta Therapeutics Inc SRPT

Healthcare Biotechnology
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy... see more

Recent & Breaking News (NDAQ:SRPT)

Sarepta Therapeutics to Present Company Overview at Upcoming Conferences

Business Wire November 4, 2014

Sarepta Therapeutics to Announce Third Quarter 2014 Financial Results and Corporate Update on November 6, 2014

Business Wire October 31, 2014

Time Magazine Warns Against Investing In Certain "Ebola Stocks"

Accesswire October 28, 2014

Sarepta Therapeutics Announces Regulatory Update on Eteplirsen

Business Wire October 27, 2014

Sarepta Therapeutics Announces Publication of Ebola and Marburg Phase I Clinical Study Results in Antimicrobial Agents and Chemotherapy

Business Wire October 16, 2014

Sarepta Therapeutics Announces Presentations at the 19th International Congress of the World Muscle Society

Business Wire October 8, 2014

Sarepta Therapeutics Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate

Business Wire September 30, 2014

Sarepta Therapeutics to Present at Leerink Partners Rare Disease Roundtable

Business Wire September 24, 2014

Sarepta Therapeutics Inc. (SRPT) Jumps 5.14% on September 10

Equities.com September 10, 2014

Sarepta Therapeutics to Present Company Overview at Upcoming Conferences

Business Wire August 28, 2014

Sarepta Enters into Partnership with Flagship Biosciences to Digitally Automate the Measurement of Dystrophin, a Key Therapeutic Efficacy Marker for Muscular Dystrophy

Business Wire August 21, 2014

Potential Payoffs Spur Big Board Biotech Action

Accesswire August 12, 2014

Sarepta Therapeutics Announces Second Quarter 2014 Financial Results and Recent Corporate Developments

Business Wire August 7, 2014

Sarepta Therapeutics Announces Appointment of John Hodgman As Interim Chairman

Business Wire July 31, 2014

Sarepta Therapeutics to Present Company Overview at Canaccord Annual Growth Conference

Business Wire July 31, 2014

Sarepta Therapeutics to Announce Second Quarter 2014 Financial Results and Corporate Update on August 7, 2014

Business Wire July 31, 2014

Sarepta Therapeutics Reports Long-Term Outcomes Through 144 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy

Business Wire July 10, 2014

Sarepta Therapeutics to Present Company Overview at the JMP Securities Healthcare Conference on June 24

Business Wire June 18, 2014

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Sarepta Therapeutics Inc. Regarding Possible Breaches of Fiduciary Duty

PR Newswire June 9, 2014

Sarepta Therapeutics Opens New Global Headquarters in Cambridge, Mass.

Business Wire June 2, 2014